Company intelligence / Profile preview
Benitec Biopharma Inc.
- Ownership
- Public · BNTC
- Employees
- ~16
- Development stage
- Other
Overview
The company’s lead program, BB‑301 for OPMD, has shown positive interim results in a Phase 1b/2a study. Treated subjects demonstrated clinically meaningful improvements in swallowing function, with some achieving clinically normal swallowing profiles. No effective drug therapies currently exist for OPMD; BB‑301 aims to address this unmet need by silencing the mutant PABPN1 gene and replacing it with a wild-type copy using AAV-mediated delivery. Additional dose escalation cohorts are ongoing.[6][8][9]
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Gene therapy (AAV-based)DNA-directed RNA interference (ddRNAi)
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $301.4M
- Total revenue
- $0
- Enterprise value
- $122.2M
Beyond the preview
Go deeper on Benitec Biopharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Benitec Biopharma Inc..